Tasia Joy Lightly

Tasia Joy Lightly

Auto-generated profile, based on publicly available information

Tasia Joy Lightly

Cytophage Technologies Limited

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in ACS Synthetic Biology
Verified
Journal Article
Closed access
AHAndrew Hogan
Andrew Hogan
ARA. S. M. Zisanur Rahman
A. S. M. Zisanur Rahman
TLTasia J. Lightly
Tasia J. Lightly
SCSilvia Cardona
Silvia Cardona

19 September 2014 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
TPTanya Pribytkova
Tanya Pribytkova
TLTasia Joy Lightly
Tasia Joy Lightly
BKBrijesh Kumar
Brijesh Kumar
SBSteve P. Bernier
Steve P. Bernier
JSJohn L. Sorensen
John L. Sorensen
SCSilvia Cardona
Silvia Cardona

1 May 2017 in Canadian Journal of Microbiology
Verified
Journal Article
Closed access
TLTasia Joy Lightly
Tasia Joy Lightly
RPRyan R. Phung
Ryan R. Phung
JSJohn L. Sorensen
John L. Sorensen
SCSilvia Cardona
Silvia Cardona
Phenylacetic acid (PAA), an intermediate of phenylalanine degradation, is emerging as a signal molecule in microbial interactions with the host. In this work, we explore the presence of phenylalanine and PAA catabolism in 3 microbial pathogens of the cystic fibrosis (CF) lung microbiome: Pseudomonas aeruginosa, Burkholderia cenocepacia, and Aspergillus fumigatus. While in silico analysis of B. cenocepacia J2315 and A. fumigatus Af293 genome sequences showed complete pathways from phenylalanine to PAA, the P. aeruginosa PAO1 genome lacked several coding genes for phenylalanine and PAA catabolic enzymes. High-performance liquid chromatography analysis of supernatants from B. cenocepacia K56-2 detected PAA when grown in Luria–Bertani medium but not in synthetic cystic fibrosis sputum medium (SCFM). However, we were unable to identify PAA production by A. fumigatus or P. aeruginosa in any of the conditions tested. The inhibitory effect of B. cenocepacia on A. fumigatus growth was evaluated using agar plate interaction assays. Inhibition of fungal growth by B. cenocepacia was lessened in SCFM but this effect was not dependent on bacterial production of PAA. In summary, while we demonstrated PAA production by B. cenocepacia, we were not able to link this metabolite with the B. cenocepacia – A. fumigatus microbial interaction in CF nutritional conditions.

1 January 2015 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
PDF file
MOMathias Kégnon Oulé
Mathias Kégnon Oulé
KSKenton Staines
Kenton Staines
TLTasia Lightly
Tasia Lightly
LRLoren Roberts
Loren Roberts
YTYannick Léandre Traoré
Yannick Léandre Traoré
LDLamine Diop
Lamine Diop
Acquired superficial fungal infections are among the most common infections. It is necessary to create new effective and non-toxic disinfectants. AKWATON is a new disinfectant of the polymeric guanidine family. Its fungicidal activity against Trichophyton mentagrophytes and its in vitro toxicity assessment were determined in this study. The MIC, minimum fungicidal concentration (MFC) and time required for its fungicidal activity at the MFC were evaluated using the official methods of analysis of the Association of Official Analytical Chemists, with modifications as recommended by the Canadian General Standards Board. The toxic effects of AKWATON and of four commercial disinfectants were evaluated on rat pancreatic (C2C12) and muscle (RnM5F) cells, using the trypan blue and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] methods. The MIC, MFC and time required for the fungicidal activity of AKWATON at the MFC were 0.025 % (w/v), 0.045 % (w/v) and 2.5 min, respectively. Cell cultures and the different tests carried out showed that the AKWATON-based disinfectant killed fewer cells than the commercial disinfectants, sparing 80 % of C2C12 cells and 65 % of RnM5F cells, whilst some of the well-known disinfectants currently on the market killed 85–100 % of cells. This study demonstrates that AKWATON has great potential as an odourless, colourless, non-corrosive and safe disinfectant for use in hospitals, the agriculture industry, farming and household facilities.

14 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
MCMelissa T. Cammuso
Melissa T. Cammuso
BCBradley William Michael Cook
Bradley William Michael Cook
DCD William Cameron
D William Cameron
SRStephen Ryan
Stephen Ryan
MTMarielou Tamayo
Marielou Tamayo
MAMarisa Ann Azad
Marisa Ann Azad
We describe the first use of phage therapy in Canada for the treatment of a life-threatening periprosthetic joint infection (PJI), with successful outcome. PJI is a devastating complication of joint replacement surgery, with high morbidity and mortality. Our patient presented with early sepsis from a chronic recalcitrant multidrug-resistant (MDR) Staphylococcus epidermidis hip PJI which had repeatedly failed standard therapy. She had previously undergone 10 operations of the right hip, and only three weeks after completing a prolonged course of daptomycin following her most recent hip revision, she developed a draining sinus tract. Given the high burden of disease, inability to achieve surgical source control, and lack of antibiotic treatment options for long-term suppressive therapy, bacteriophage (phage) therapy was pursued. The patient underwent irrigation and debridement with complex flap reconstruction: intraoperative tissue cultures again yielded MDR S. epidermidis. We developed a novel phage therapy protocol for this patient, with twice daily, intra-articular and intravenous (7 × 109 PFU/dose) phage delivery over a planned 14-day course. Complete healing of the wound with cessation of drainage occurred within one month after treatment. A marked improvement in right hip pain and mobility occurred within three months after treatment. Twelve months following phage treatment, there is normalization of serum inflammatory markers with diminished pain, increased mobility, and no recurrent surgery. Our patient continues to improve and is currently living independently at home, with sustained clinical control of infection.

9 July 2026 in Microbiology Resource Announcements
Verified
Journal Article
Open access
NFNicolas Fournier
Nicolas Fournier
STSteven S. Theriault
Steven S. Theriault
TLTasia Joy Lightly
Tasia Joy Lightly
With the purpose of finding phages that can target Manitoba farm isolates of Streptococcus suis , we began the characterization of a control strain, Streptococcus sp. bacteriophage 118 (ATCC 19951-B2). Here we describe the genome sequencing and reclassification of the 154,261-bp virus as an Enterococcus phage.